Pular para o conteúdo principal
Ranking Invest

SRPT - Sarepta Therapeutics, Inc.

Segmento: HealthcareSarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping. The company is also developing AMONDYS 45, a product candidate that uses phosphorodiamidate morpholino oligomer chemistry and exon-skipping technology to skip exon 45 of the dystrophin gene; SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Lysogene; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

Análise Ranking Invest

Valuation estimado
$ 460.67 Mi
Valor de Mercado
$ 2.16 Bi
Sobrepreço (AV)+368.9%
IVR
0.21A companhia vale 0,21 vezes o seu valor de mercado atual de acordo com a estimativa do Ranking Invest.
IVR2
-0.48O valuation alternativo equivale a -48% do valor de mercado da companhia.
MLL
-0.48O lucro líquido dos controladores em 16 trimestres equivale a -48% do valor de mercado.
Último Balanço Atualizado: 2T2026

O Ranking Invest utiliza metodologia própria baseada em dados financeiros objetivos, considerando patrimônio, lucratividade e endividamento para estimar o valuation das empresas.

Dados da Empresa

Patrimônio Líquido

$ 1.53 Bi

Dívida Líquida

$ 276.48 Mi

L4T

-$ 266.10 Mi

MM4T

-23.51%

Indicadores Básicos

ROE

-17.42%

Índices de Previsibilidade

Receita Líquida

E0.19

Lucro

G15.30

Margem

F5.46

Índices de Tendência

Receita Líquida

B8.27

Lucro

C3.15

Margem

B4.85

Índices de Endividamento

DIV/PAT

0.18

DIV/L4T

-1.04

Dívidas
Cotação
Gráfico Lucro/Receita Líquida X TrimestrePor padrão são exibidos os últimos 16 trimestres; quando houver mais trimestres disponíveis, use o botão junto à tabela de resultados para expandir o histórico.